Statera Biopharma, Inc. Nasdaq

Equities

STAB

US8575611046

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 11:37:36 2024-04-29 am EDT			5-day change	1st Jan Change
0.0007 ^USD	0.00%		0.00%	-99.98%

2023	Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs.	CI
2023	Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index	CI

Cleveland Biolabs, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019

November 14, 2019 at 05:05 pm EST

Cleveland BioLabs, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced operating loss was USD 518,396 compared to USD 1.267 million a year ago. Net loss was USD 449,919 compared to USD 1.104 million a year ago. Basic loss per share was USD 0.04 compared to USD 0.1 a year ago. For the nine months, operating loss was USD 2.080 million compared to USD 4.171 million a year ago. Net loss was USD 1.939 million compared to USD 3.180 million a year ago. Basic loss per share was USD 0.17 compared to USD 0.28 a year ago.

Latest news about Statera Biopharma, Inc.

Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs.	23-03-14	CI
Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index	23-01-17	CI
Statera Biopharma, Inc.(OTCPK:STAB) dropped from NASDAQ Composite Index	23-01-11	CI
Statera Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Statera Biopharma, Inc. announced that it has received $0.4 million in funding from Silverback Capital Corporation	22-11-06	CI
Statera Biopharma, Inc. announced that it expects to receive $0.765 million in funding	22-10-31	CI
Statera Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-10-28	CI
Statera Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-10-21	CI
US Futures Lower Amid Earnings Reports, Ahead of Flash PMI Data	22-10-21	MT
Top Premarket Gainers	22-10-21	MT
Top Premarket Decliners	22-10-18	MT
Statera Biopharma, Inc. entered a Binding Memorandum of Understanding to acquire 25% in Holobeam Technologies, Inc. for $25 million.	22-10-16	CI
Top Premarket Decliners	22-10-07	MT
Wall Street Set to Open Lower as Jobless Claims Rise	22-10-06	MT
US Futures Lower as Prices Fuel Investors' Inflation Concerns	22-10-06	MT
Top Premarket Gainers	22-10-06	MT
Statera Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-10-06	CI
Statera Biopharma, Inc. Auditor Raises 'Going Concern' Doubt	22-10-05	CI
Certain Warrants of Statera Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 18-SEP-2022.	22-09-17	CI
Certain Options of Statera Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 18-SEP-2022.	22-09-17	CI
Certain Restricted stock units of Statera Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 18-SEP-2022.	22-09-17	CI
Certain Common Stock of Statera Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 18-SEP-2022.	22-09-17	CI
Statera Biopharma, Inc. Announces Board Changes	22-09-09	CI
Statera Biopharma Receives Additional Non-Compliance Notice From Nasdaq	22-08-26	MT
Statera Biopharma Stock Trading Halted Pending Nasdaq's Information Request	22-08-25	MT

Chart Statera Biopharma, Inc.

Duration

Period

More charts

Company Profile

Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the bodyâs immune system and restore homeostasis. It has platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. The Company is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohnâs disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+0.54%	42.86B
MODERNA, INC.	+12.09%	42.74B
LONZA GROUP AG	+44.30%	41.36B
CELLTRION, INC.	-6.20%	27.68B
ICON PUBLIC LIMITED COMPANY	+5.82%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.81%	18.63B
MEDPACE HOLDINGS, INC.	+28.22%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.61%	11.92B
UNITED THERAPEUTICS CORPORATION	+7.00%	11.21B

Other Biotechnology & Medical Research